Algert Global’s Axsome Therapeutics AXSM Stock Holding History

Algert Global’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.3M	Sell	95,335 -40,125	-30%	-$8.7M	0.28%	63
2026 Q1	$22.9M	Sell	135,460 -13,932	-9%	-$2.41M	0.34%	41
2025 Q4	$27.3M	Buy	149,392 +105,242	+238%	+$14.7M	0.43%	24
2025 Q3	$5.36M	Buy	44,150 +6,720	+18%	+$757K	0.09%	391
2025 Q2	$3.91M	Buy	37,430 +11,490	+44%	+$1.22M	0.08%	410
2025 Q1	$3.03M	Buy	+25,940	New	+$2.96M	0.07%	458
2024 Q3	–	Sell	-3,105	Closed	-$250K	–	1209
2024 Q2	$250K	Buy	+3,105	New	+$230K	0.01%	1197
2022 Q4	–	Sell	-6,040	Closed	-$270K	–	1138
2022 Q3	$270K	Buy	+6,040	New	+$302K	0.02%	970

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Algert Global's AXSM Position: Q2 2026 in Review

Algert Global reduced its Axsome Therapeutics (AXSM) stake by 30% in Q2 2026, selling an estimated $8.7M and leaving 95,335 shares worth $23.3M. The position accounts for 0.28% of the portfolio, ranked #63.

Algert Global first reported a position in AXSM in Q3 2022 and has held it in 8 quarters since. The position peaked at $27.3M in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Algert Global held 95,335 shares of Axsome Therapeutics worth $23.3M as of Q2 2026.
Algert Global sold 40,125 Axsome Therapeutics shares in Q2 2026, an estimated $8.7M.
Axsome Therapeutics made up 0.28% of Algert Global's portfolio in Q2 2026, its #63 holding.
Algert Global first reported a position in Axsome Therapeutics in Q3 2022 and has held it in 8 quarters since.
Algert Global's Axsome Therapeutics position peaked at $27.3M in Q4 2025.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.